BSD Medical is Now Pyrexar Medical

The First Affiliated Hospital of Zhengzhou University celebrated the opening of its thermal oncology center located in the Henan province of mainland China.  The hospital constructed a custom hyperthermia suite to house the BSD-2000 Deep Regional Hyperthermia system built by Pyrexar Medical.  First Affiliated has a long history of hyperthermic clinical research and plans to further pioneer its use, in addition to general clinical use for their cancer patients.

Often referred to as "the largest hospital in the world", First Affiliated offers 7,000 beds. Compare that to the largest medical center in the US, New York-Presbyterian at 2,678 and you get to understand the colossal scale of the facility.

The opening celebration included a presentation ceremony, lectures on hyperthermia in the treatment of cancer, and a tour of the facility, attracting physicians and medical professionals from the area.

What does that mean for the future of hyperthermia in China? Thermal therapy has long been accepted in Asia and is growing steadily. The prestige,  influence, and access of a medical facility of this magnitude is expected to result in accelerated demand for Pyrexar system installations throughout China.

A special thanks to the talented team at our distributor Dalian Orientech for their dedication to bringing the best in medical technology to the region.

The link between increased longevity and hyperthermia treatment was considered a landmark study when it published in late 2018 in the Journal of the American Medical Association.

Recently, our partners at Sennewald Medizintechnik, caught up with renowned expert and cancer study co-author Professor Dr. Lars Lindner of Ludwig-Maximilians-Universität (LMU) in Munich to get a deeper understanding of the findings.

After examining over 30 Soft Tissue Sarcoma trials, Prof. Dr. Linder lists the top four significant findings:

1. Doxorubicin-based chemotherapy is and remains the standard of care for soft tissue sarcomas.
2. The benefit of chemotherapy has also been shown in the adjuvant situation in high-risk patients.
3. Neoadjuvant therapy is preferable because it combats potential micrometastasis at the earliest possible time and improves operability.
4. Regional hyperthermia improves the effectiveness of chemotherapy and leads to improved patient survival.

The complete interview is available on the Sennewald Medizintechnik April 2021 newsletter.

The 2020 ESHO-Pyrexar Award presentation included the history and merits of Professor Niloy Datta, celebrating his achievements in the field of thermal oncology.  What follows the award presentation is nothing less than a Master Class in thermal oncology.  Dr. Datta shares highlights of his research and his vision for the pathway to hyperthermia expansion and success.

Along with presenting evidence of the increased value to the patient that hyperthermia brings, Dr. Datta also touches on the financial rationale of adding a thermal oncology program to your hospital.

Below find a summary of recently published works involving hyperthermia by Datta et al.

 A special thanks to Dr. Sennewald Medizintechnik for sponsoring the award and presentation.

Medical news may be dominated by pandemic coverage, but cancer research still moves forward.  We did a quick search on clinicaltrials.gov for trials using hyperthermia as an adjunct to radiotherapy, chemotherapy, and immunotherapy.  The listing below is a summary of studies around the world. 

HIPEC studies have not been included in this list. Listing facilities with Pyrexar hyperthermia systems is not a statement that those systems are used in the study, only that they exist at the facilities conducting the study.  If you know of a study not included in the list, please let us know, and we would be happy to share it on our website.